1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis A - Drugs In Development, 2022, provides an overview of the Hepatitis A (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Hepatitis A is inflammation of the liver caused by hepatitis A virus. Symptoms include fatigue, nausea and vomiting, inflammation of the liver, loss of appetite, dark urine, muscle pain and yellowing of the skin and eyes (jaundice). Risk factors include weakened immune system and use injected or non-injected illicit drugs. Treatment includes antiemetics and pain relievers.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Hepatitis A - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hepatitis A (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hepatitis A (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 3, 4, 1, 2 and 1 respectively.
Hepatitis A (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis A (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hepatitis A (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatitis A (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatitis A (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis A (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatitis A (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hepatitis A (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Hepatitis A - Overview
- Hepatitis A - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Hepatitis A - Therapeutics Assessment
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hepatitis A - Companies Involved in Therapeutics Development
- Biological E Ltd
- Boryung Pharmaceutical Co Ltd
- China National Pharmaceutical Group Corp
- Etna Biotech Srl
- F. Hoffmann-La Roche Ltd
- Indian Immunologicals Ltd
- Liaoning Cheng Da Biotechnology Co Ltd
- Novo Medi Sciences Pvt Ltd
- Sinovac Biotech Ltd
- SK Bioscience Ltd
- Zydus Lifesciences Ltd
- Hepatitis A - Drug Profiles
- Product Description
- Mechanism Of Action
- BR-8003 - Drug Profile
- Product Description
- Mechanism Of Action
- hepatitis A + hepatitis B vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- hepatitis A [strain (RGSB)] vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- hepatitis A vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- hepatitis A vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- hepatitis A vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- hepatitis A vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- hepatitis A vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- hepatitis A vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- RG-7834 - Drug Profile
- Product Description
- Mechanism Of Action
- Hepatitis A - Dormant Projects
- Hepatitis A - Product Development Milestones
- Featured News & Press Releases
- Jul 05, 2022: UNC team discovers interactions vital for hepatitis A virus replication
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Hepatitis A, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Hepatitis A - Pipeline by Biological E Ltd, 2022
- Hepatitis A - Pipeline by Boryung Pharmaceutical Co Ltd, 2022
- Hepatitis A - Pipeline by China National Pharmaceutical Group Corp, 2022
- Hepatitis A - Pipeline by Etna Biotech Srl, 2022
- Hepatitis A - Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Hepatitis A - Pipeline by Indian Immunologicals Ltd, 2022
- Hepatitis A - Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, 2022
- Hepatitis A - Pipeline by Novo Medi Sciences Pvt Ltd, 2022
- Hepatitis A - Pipeline by Sinovac Biotech Ltd, 2022
- Hepatitis A - Pipeline by SK Bioscience Ltd, 2022
- Hepatitis A - Pipeline by Zydus Lifesciences Ltd, 2022
- Hepatitis A - Dormant Projects, 2022
- Number of Products under Development for Hepatitis A, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Biological E Ltd
- Boryung Pharmaceutical Co Ltd
- China National Pharmaceutical Group Corp
- Etna Biotech Srl
- F. Hoffmann-La Roche Ltd
- Indian Immunologicals Ltd
- Liaoning Cheng Da Biotechnology Co Ltd
- Novo Medi Sciences Pvt Ltd
- Sinovac Biotech Ltd
- SK Bioscience Ltd
- Zydus Lifesciences Ltd
